-PTI PATNA: CAG has ticked off Nitish Kumar government for lacking objective planning for utilisation of funds drawn on Abstract Contingency(AC) bills. The Bihar government had withdrawn Rs 16,033.01 crore on AC bills between 2009-12 of which the plan head drawals accounted for Rs 12,332.64 crore which indicated that object level planning was absent as items of expenditure were known while drawing the amount, CAG said in its report on state finances...

-The Hindu At the foothills of Datla mountain of Satpuda Valley in the Hoshangabad district of Madhya Pradesh is located the picturesque village of Dhadaw. Located on the banks of Dudhi River that also defines the boundary of the district, Dhadaw falls in the district's forest belt. Within the periphery of this village lies a world that has efficiently maintained the essence of traditional agricultural practices - a remarkable feat at...

-The Hindu   Despite apparent similarities, the reports of two centrally appointed committees are split on the relationship between knowledge, skills and social needs Two major reports with overlapping concerns were submitted to the central government during the last decade. They were drafted by committees appointed by two different offices of the same government. One was chaired by Yash Pal, and the other by Sam Pitroda. The titles of the two committees indicated...

-The Hindu The Justice Verma Committee report acts as a blueprint for the radical transformation of gender relations within the framework of constitutional guarantees and gender equality. However, the adoption of the Criminal Law Amendment Act 2013 by Parliament on March 19, 2013, does not go beyond legal change. Prof. Hasan argues that if political parties are serious about the rights of women, the Women's Representation Bill must be passed...

-The Hindu   Supreme Court rejects Novartis' plea for patent; green signal for cheaper generic drugs In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a well known cancer-fighting drug is not a patentable new invention. The judgment allows suppliers to continue making generic copies of Swiss firm Novartis' Glivec or Gleevec, which has been shown to...